Search research articles
Contact Us
Filters
Showing results (71-80 of 96) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
The Lancet. Oncology
|
March 21, 2021
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, et al.
Bulletin Du Cancer
|
March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]
Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Genes, Chromosomes & Cancer
|
March 14, 2024
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation
Quitterie Fontanges, Paul Dubos, Tom Lesluyes, et al.
Cancers
|
August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
Marta Bini, Stanislas Quesada, Pierre Meeus, et al.
Gynecologic Oncology
|
May 21, 2023
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study
Brunhilde Hanvic, Fabrice Lecuru, Hélène Vanacker, et al.
Gynecologic Oncology
|
July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database
Alexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Gynecologic Oncology
|
October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
BMC Medical Ethics
|
October 23, 2016
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study
David J Pulford, Philipp Harter, Anne Floquet, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 96) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
The Lancet. Oncology
|
March 21, 2021
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, et al.
Bulletin Du Cancer
|
March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]
Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Genes, Chromosomes & Cancer
|
March 14, 2024
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation
Quitterie Fontanges, Paul Dubos, Tom Lesluyes, et al.
Cancers
|
August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
Marta Bini, Stanislas Quesada, Pierre Meeus, et al.
Gynecologic Oncology
|
May 21, 2023
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study
Brunhilde Hanvic, Fabrice Lecuru, Hélène Vanacker, et al.
Gynecologic Oncology
|
July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database
Alexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Gynecologic Oncology
|
October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
BMC Medical Ethics
|
October 23, 2016
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study
David J Pulford, Philipp Harter, Anne Floquet, et al.
Page
of 10